Minerva Neurosciences Inc (NERV NASDAQ) stock market data APIs
$2.266
-0.13(-5.7%)
as of September 15, 2025
Try our APIs with
free plan!
Minerva Neurosciences Inc Financial Data Overview
Price chart is built with
Anychart
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Prev. Close
2.266
Open
2.1384
High
2.266
Low
2.0647
52 wk Range
1.15-2.98
Market Cap
15 246 K
P/E Ratio
1.473
Shares Outstanding
6 993 K
EPS
-0.43
Beta
-0.274
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Minerva Neurosciences Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Minerva Neurosciences Inc data using free add-ons & libraries
Get Minerva Neurosciences Inc Fundamental Data
Minerva Neurosciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -16 160 446
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.9
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Minerva Neurosciences Inc News
New
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
FDA confirms requirement for confirmatory study of roluperidone for the treatment of negative symptoms in schizophrenia Evaluation of strategic alternatives BURLINGTON, Mass., Aug. 14, 2025 (GLOBE...
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
BURLINGTON, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ne...
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
BURLINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central n...
12 Best Performing Biotech Stocks in 2023
In this piece, we will take a look at the 12 best performing biotechnology stocks in 2023. If you want to skip our introduction to the biotechnology industry and some top players, then check out 5 Bes...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
